Scholar Rock

SRRK

Market cap $5.46B

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK; the “Company”) today announced that the company granted inducement equity awards covering an aggregate of 89,304 shares of its common stock to nine newly hired employees, consisting of inducement stock options to purchase an aggregate of 38,331 shares of common stock and inducement restricted stock units, covering an aggregate of 50,973 shares of its common stock. The awards are subject to all terms and conditions and other provisio.

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK) today announced that it will report first quarter 2026 financial results on Thursday, May 7, 2026, before the financial markets open. The Company will host a conference call and webcast with Scholar Rock management at 8:00 a.m. ET. To access the live audio webcast, please go to “Events and Presentations” in the Investors section of the Scholar Rock website at http://investors.scholarrock.com. To participate via telephone, please reg.

Scholar Rock stock jumps 14% after it resubmits its FDA filing for SMA drug apitegromab, revives approval hopes and sets up a potential September 2026 decision.

Scholar Rock Holding Corporation (SRRK) Discusses BLA Resubmission for Apitegromab in Spinal Muscular Atrophy and Regulatory Progress Transcript

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to improving the lives of children and adults with spinal muscular atrophy (SMA) and additional rare, severe, and debilitating neuromuscular diseases by applying its leading platform in myostatin biology to advance musculoskeletal health, today announced it has resubmitted the Biologics License Application (BLA) for apitegromab for the treatment of children and adults with SMA to the U.S.

Scholar Rock (SRRK) is transitioning from regulatory uncertainty to a clear execution path for a 2026 US launch of apitegromab. Resolution of FDA manufacturing concerns at Catalant's facility and resumed operations significantly de-risk the regulatory timeline for SRRK. A $550M non-dilutive debt facility and $370M cash position strengthen SRRK's balance sheet, minimizing dilution risk.

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK; the “Company”) today announced that the company granted inducement equity awards covering an aggregate of 60,655 shares of its common stock to five newly hired employees, consisting of inducement stock options to purchase an aggregate of 24,506 shares of common stock and inducement restricted stock units, covering an aggregate of 36,149 shares of its common stock. The awards are subject to all terms and conditions and other provisio.

Scholar Rock Holding Corporation (SRRK) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

Scholar Rock Holding Corporation (SRRK) Q4 2025 Earnings Call Transcript

CAMBRIDGE, Mass.--(BUSINESS WIRE)--In the release, the first paragraph of the Fourth Quarter and Full Year 2025 Financial Results section, second sentence should read: Net loss per common share was $0.76 for the quarter ended December 31, 2025, compared to $0.61 per common share for the quarter ended December 31, 2024. (instead of Net loss per common share was $0.88 for the quarter ended December 31, 2025, compared to $0.61 per common share for the quarter ended December 31, 2024.) In the Conde.